52 results about "Ventricular hypertrophy" patented technology

Techniques are provided for predicting the onset of a heart condition within a patient based on impedance measurements. Briefly, overloads in fluid levels in the thorax and in ventricular myocardial mass within the patient are detected based on impedance signals sensed using implanted electrodes. The onset of certain heart conditions is then predicted based on the overloads. For example, pulmonary edema arising due to diastolic heart failure is predicted based on the detection of on-going overloads in both fluid levels and ventricular mass. Ventricular hypertrophy is detected based on an on-going ventricular mass overload without a sustained fluid overload. Various other heart conditions may also be predicted based on specific combinations of recent or on-going overloads. Evoked response is exploited to corroborate the predictions. Appropriate warning signals are generated and preemptive therapy is initiated.

Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.

The invention relates to a medicinal composition, which consists of the following parts: a calcium ion antagonist (CCB) or pharmaceutically acceptable salt thereof, an angiotensin II acceptor antagonist (ARB) or pharmaceutically acceptable salt or ester thereof, statins or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention also relates to a combined kit containing the active substances. The medicinal composition or the kit is used for treating hypertension, dyslipidemia, cerebrovascular disorder, stroke, coronary heart disease, diabetes, diabetic complication, angina, myocardial infarction, cardiac insufficiency, renal dysfunction, atherosclerosis, ventricular hypertrophy, aneurysm, myocardial ischemia, arrhythmia and glaucoma of patients, reducing the incidence rate and / or the death rate of cardiovascular and cerebrovascular disease, improving the adaptability of drug administration of the patients at the same time, and improving the life quality of the patients.

Disclosed herein are methods of detecting, monitoring, and predicting left ventricular hypertrophy, congestive heart failure and related conditions by profiling biomarkers.

The present invention relates to the new use of alpha-ketoglutarate, amides, and salts and mixtures thereof for the manufacture of a pharmaceutical preparation or a food or feed supplement for the in vivo therapeutic improvement of blood vessel elasticity, in particular arterial elasticity in a subject in need thereof. Improving the blood vessel elasticity may be used in the for the treatment and / or prophylaxis of hypertension, pulmonary arterial hypertension, cardiovascular disease, retinal vascular disease, heart failure, atherosclerosis, ventricular hypertrophy, stroke, arterial aneurysm, kidney failure, nephrosclerosis and diseases related to hypertension.

Myocardial hypertrophy is a pathological change of a plurality of kinds of angiocardiopathy. The main mode is the heart remodeling comprising cardiac muscle cell hypertrophy and change of the interstitial tissue component mainly. In the present invention, the nitrate medicine is used in treatment for myocardial hypertrophy caused by various reasons and excellent therapy effect is obtained. Currently the nitrate medicine is extensively applied in treatment for the coronary heart disease, the heart colicky pain and heart failure. Preload of the heart and myocardial consumption of oxygen are reduced by extension of the venous system. The drugs used in clinical field currently comprise Nitroglycerin, Amyl Nitrite, dicho nitric acid sorbite, sorbide dinitrate, 5-isosorbide dinitrate, Nitroglycerin, pentanitrol ters and itramine tosylate.

The invention discloses a construction method of a diabetic cardiomyopathy animal model. An SD (Sprague Dawley) rat under high-sugar and high-fat feeding is subjected to multiple abdominal injection with STZ (streptozocin); after the diabetics diagnosis standard is reached, subcutaneous injection with isoprenaline is performed; after 2 weeks of continued feeding, left ventricular cannulation and three-lead electrocardiogram test of ventricular hemodynamic parameters and electrocardiogram parameters shows that the rat experiences cardiac dysfunction; heart weight index and left ventricular index show that the rat experiences evident ventricular hypertrophy; biochemical analysis on rat blood shows that the rat has evident myocardial damage; HE (hematoxylin-eosin) pathological staining satisfies pathological changes in diabetic cardiomyopathy; Masson collagen staining satisfies myocardial connective tissue proliferation of diabetic cardiomyopathy. The construction method has the advantages of good operational simplicity, short construction time, low mortality in construction phase, high construction success rate and the like, and the pathological process of myocardial damage due to human type 2 diabetes mellitus can be well simulated.

A method and system for managing an implantable medical device (IMD) based on left ventricular hypertrophy (LVH) are provided. The method collects cardiac activity (CA) signals from one or more implantable electrodes at corresponding sensing sites. The method utilizes one or more processors to perform identifying a characteristic of interest from the CA signals, analyzing the characteristic of interest from the CA signals to identify an LVH state indicative of at least one of an occurrence or degree of LVH experienced by the patient, calculating a DFT expectation based on the LVH state and determining, based on the DFT expectation, at least one of i) a defibrillation shock parameter or ii) a maximum energy capacity of the IMD for implant.

The invention relates to a drug composition for curing cardiovascular system diseases and the key point is that the invention which combines sartans, aldosterone receptor antagonist and isosorbide mononitrate according to certain proportions becomes a novel drug which cures the cardiovascular system diseases such as hypertension and heart failures and achieves ideal treatment effects comprehensively considered. The invention has the advantages that 1. The invention has a good effect in anti-myocardial fibrosis anti-ventricular hypertrophy as well as effective antihypertensive. 2. The invention is good in treating simple systolic hypertension of the elderly, exact in hypertensive effect, stable in operation and has no drug resistance. 3. The invention has active influences on the prognosis of patients of hypertension and the related complications, which is also the most meaningful clinical treatment problems which are solved by the invention.

The invention relates to a Chinese patent medicament taking plants as raw materials, in particular to a medicinal composition for treating hypertension left ventricular hypertrophy, which consists of active ingredients and pharmaceutically-acceptable auxiliary materials. The medicinal composition is characterized in that the active ingredients are prepared from the following raw material medicaments in percentage by weight: 15 to 50 percent of astragalus, 10 to 20 percent of yellowmouth dutchmanspipe root, 5 to 25 percent of notoginseng root, 5 to 25 percent of root of red-rooted salvia, 5 to 25 percent of ground beeltle, 5 to 20 percent of snakegourd fruit, 5 to 20 percent of gambir plant and 5 to 20 percent of tall gastrodia tuber. By combining the medicaments of the medicinal composition according to a formula, the medicinal composition has the effects of replenishing qi and invigorating blood circuit and reducing phlegm and calming the liver, and has the advantages of readily available medicinal materials and moderate cost.

Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and / or of hospitalization due to chronic heart failure and / or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.

The invention relates to novel application of a medicine, and in particular relates to an adjuvant treatment effect of tofacitinib on senile degenerative valvular disease. A clinical trial research shows that while conventional treatment is carried out on a patient with the senile degenerative valvular disease, the tofacitinib can be given for adjuvant treatment; the tofacitinib can be used for remarkably treating lung extravasated blood and pleural effusion symptoms of the patient with the senile degenerative valvular disease; various arrhythmia including auricular fibrillation and the like, atrial hypertrophy and ventricular hypertrophy are effectively relieved; the recurrence rate of the disease can be reduced, and the life quality of the patient is improved.

The invention relates to purposes of polygonum cuspidatum extract, namely polydatin. Myocardial hypertrophy is the most important reason for triggering congestive heart failure. Ventricular hypertrophy usually involves ventricular structure change, namely ventricular remodeling. The ventricular remodeling is a complication of multiple cardiovascular diseases and a vital and decisive element in the development process of the congestive heart failure. The arrhythmia occurrence rate after the myocardial remodeling is increased by 28%, and cardiac sudden deaths caused in the end are increased by over five times. It is indicated that through in vitro study tests, the polydatin remarkably restrains heart ion channels caused by ischemia indury of mice from remodeling and has a great protective effect for arrhythmia, and therefore the polydatin can be used for preparing products resisting against arrhythmia caused by myocardial hypertrophy and / or ventricular hypertrophy. According to the method, the polydatin plays the anti-arrhythmic role by increasing the electric current density of transient outward potassium current (Ito), shortening the action potential duration (APD) of cardiac muscle cells and restraining the QT inter-phase from being prolonged.

The invention discloses a pharmaceutical composition for treating hypertensive left ventricular hypertrophy; the pharmaceutical composition comprises total glucosides of paeony and at least one angiotensin converting enzyme inhibitor; the angiotensin converting enzyme inhibitor is captopril, enalapril, perindopril or fosinopril. The pharmaceutical composition has very significant reverse effect on hypertension induced ventricular hypertrophy; by adopting the pharmaceutical composition, the perfect synergy function on each index such as left ventricular index of myocardial hypertrophy is obtained.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

The invention discloses a ventricular hypertrophy prediction system and device and a storage medium. The system comprises an acquisition module used for acquiring electrocardiogram data of a to-be-predicted person in multiple lead modes; a grouping module, which is used for grouping the lead modes and dividing the electrocardiogram data according to a grouping result of the lead modes to obtain a plurality of electrocardiogram data groups; a prediction module, which is used for inputting the electrocardiogram data groups into different prediction models to obtain first prediction results corresponding to the electrocardiogram data groups, wherein the first prediction result is used for representing whether the person to be predicted has ventricular hypertrophy; and a processing module, which is used for obtaining a ventricular hypertrophy prediction result of the person to be predicted according to a weighted result of each first prediction result. The method can effectively overcome the problem of low prediction result precision caused by a single data source and a single prediction model. The method can be widely applied to the technical field of artificial intelligence.

The invention relates to a medicine composition used for treating hypertension and an application thereof. The invention provides a medicine composition, containing aliskiren and rosuvastatin, aiming at improving a curative effect, improving prognosis of a patient, reducing occurrence of cardiovascular and cerebrovascular diseases caused by the hypertension and improving effective protection on important organs of a hyperpietic such as heart, brain, kidney and the like. Pharmacodynamic experiments verify that the medicine composition provided by the invention has synergic treatment effects in the aspects of reducing blood pressure, reversing or alleviating left ventricular hypertrophy and reducing microdose albumin in urine, is effective in the aspect of preventing hypertensive renal disease and can delay or reduce occurrence of nephropathy of the hyperpietic.

The invention discloses a traditional Chinese medicine composition for treating hypertension-concurrent left ventricular hypertrophy and a preparation method thereof. The traditional Chinese medicinecomposition is prepared from, by weight, 8-20 parts of the roots of red-rooted salvia, 5-20 parts of sappanwood, 5-20 parts of pinellia ternate, 5-20 parts of pericarpium citri reticulatae, 5-20 partsof poria cocos and 3-10 parts of honey-fried licorice roots. The traditional Chinese medicine composition has the functions of promoting blood circulation, removing blood stasis, drying dampness andclearing phlegm, the compatibility is reasonable, cooperative interaction is achieved, the curative effect can be improved, and thus the traditional Chinese medicine composition can treat middle-latestage hypertension left ventricular hypertrophy symptoms which include vertigo, head feeling heavy with a vise or headache with a stab, fixed pain, chest tightness and breath shortness, palpitation and insomnia, abdominal distension, tastelessness and little appetite, emesis and salivation, a dark tongue, white and greasy moss, wiry and rolling pulses or astringent pulses and the like. The traditional Chinese medicine composition has the advantages of safety, reliability, no dependence, remarkable clinical effects and stable and controllable quality. The traditional Chinese medicine composition is extracted by adopting percolation, and can be made into capsules, pills and ointment.

The invention discloses an application of neuraminidase and inhibitors thereof in preparation of drugs for treating myocardial fibrosis and ventricular hypertrophy. Zanamivir and oseltamivir phosphateare known as effective inhibitors of neuraminidase, and an inhibitory effect of coptisine on neuraminidase also is published in an applicant previous patent application; salvianolic acid B is also found to be able to inhibit the activity of neuraminidase in vitro, and is a neuraminidase inhibitor; experiments prove that the multiple kinds of neuraminidase inhibitors can effectively inhibit the activity of neuraminidase in myocardium in vivo, then inhibit myocardial fibrosis and ventricular hypertrophy, and can be used for treating heart disease caused by myocardial fibrosis and ventricular hypertrophy. Therefore, neuraminidase and the inhibitors thereof can be used for preparation of the drugs for treating myocardial fibrosis and ventricular hypertrophy.